Search results
Results from the WOW.Com Content Network
Cancer specific T-cells can be obtained by fragmentation and isolation of tumor infiltrating lymphocytes, or by genetically engineering cells from peripheral blood. The cells are activated and grown prior to transfusion into the recipient (tumor bearer).
Fig. 1. Processing of tumor antigens recognized by CD8 + T cells. T lymphocytes are cells of the immune system that attack and destroy virus-infected cells, tumor cells and cells from transplanted organs. This occurs because each T cell is endowed with a highly specific receptor that can bind to an antigen present at the
Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen. Dendritic cells are antigen-presenting cells (APCs) in the mammalian immune system. [15] In cancer treatment, they aid cancer antigen targeting ...
The adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) [27] [28] [29] or genetically re-directed peripheral blood mononuclear cells [30] [31] has been used experimentally to treat patients with advanced solid tumors, including melanoma and colorectal carcinoma, as well as patients with CD19-expressing hematologic malignancies ...
A portion of the recipient's tumor tissue is removed during a surgical procedure prior to treatment. [3] The recipient's T cells (the tumor-infiltrating lymphocytes) are separated from the tumor tissue, multiplied and then infused into the patient in a single dose. [3] T cells are a type of cell that helps the immune system fight cancer and ...
These lesions may occur at multiple sites or spread throughout large areas of the GI tract. Biopsied tissues show abnormally broad intestinal villi caused by the infiltration of sheets of uniformly-sized lymphocytes. These lymphocytes may also infiltrate and disrupt the architecture of nearby intestinal crypts and the epithelial lining.
Some cancers that form tumors, such as breast cancer, produce CCL17 which draws T regulatory cells into the area, enhancing the cancer’s ability to invade. [6] On the other hand, CCL17 will also activate tumor-infiltrating lymphocytes tumors. [ 6 ]
Cellular adoptive therapy is another alternative for these patients. The first studies with tumor-infiltrating lymphocytes (TILs) were performed at the Surgery Branch in the National Institutes of Health. These studies used TILs grown from different murine tumors and showed in vivo anti-tumor activity of these cells.